• Novo Nordisk sues Eli Lilly over allegations of misleading advertising.
• The lawsuit claims Lilly used outdated data to suggest superiority of its drugs.
• Novo seeks a court order for corrective advertising from Eli Lilly.
• The growing competition in the weight-loss drug market is highlighted.
• FDA approved newer doses of Novo's drugs provide a basis for the lawsuit.

In a significant legal move, Novo Nordisk has filed a lawsuit against Eli Lilly in U.S. federal court, accusing it of false advertising regarding its obesity medications. The Danish pharmaceutical company claims that Eli Lilly's ads suggest its weight-loss drugs outperform Novo's offerings by utilizing outdated clinical trial data. Specifically, Novo alleges that Lilly’s advertisements inaccurately compare the highest doses of its drugs to lower doses of Novo's Wegovy and Ozempic, thereby misrepresenting their efficacy and violating federal and state laws, including the Lanham Act, according to Reuters and BBC.

Moreover, the lawsuit points out that while Eli Lilly’s drug Zepbound was reported to have a greater average weight loss in a head-to-head trial—50 pounds compared to Wegovy's 33 pounds—Novo argues that the comparison fails to account for its recently FDA-approved higher doses. These newer doses reportedly provide superior outcomes, thus invalidating the comparisons made by Lilly, as outlined in various reports including Los Angeles Times and CBS News.

In addition to seeking a court order for Eli Lilly to cease its misleading ads, Novo Nordisk is also pursuing a "corrective advertising campaign" that aims to clarify the misinformation presented to consumers. The company emphasizes that factual transparency is vital for patients' care decisions, as stated by John Kuckelman, Novo's general counsel. He noted that “healthcare companies have a responsibility to keep their public claims accurate and current," citing the competitive nature of the healthcare market as a justification for this action, reported by Reuters and Los Angeles Times.

As this lawsuit unfolds, it reflects the escalating competition in the rapidly expanding market for weight-loss drugs, projected to surpass $120 billion by 2030. Novo and Eli Lilly are in fierce contention for market dominance, with Novo seeking to recover lost profits and ensure accurate consumer information is disseminated amidst the legal dispute, according to CBS News and BBC.